Control
Tiprelestat is a recombinant human elafin protein administered intravenously that acts as an anti-inflammatory agent through reversible inhibition of neutrophil elastase and proteinase 3, aiming to attenuate neutrophil-driven lung injury in severe COVID-19.
Recent:Bergs.
Sep 16 2025 |
et al., Advances in Therapy, doi:10.1007/s12325-025-03362-w | Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial |
| 189% higher mortality (p=1), 11% lower progression (p=1), 22% shorter ICU admission (p=0.85), and 40% lower need for oxygen therapy (p=0.52). RCT 17 hospitalized COVID-19 patients showing no significant differences with tiprelestat (recombinant human elafin, a neutrophil elastase inhibitor). There was a trend toward benefit for oxygen support. | ||